- Stocks
- Healthcare
- NASDAQ: ORTX

Price (delayed)

$1.27

Market cap

$159.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.23

Enterprise value

$141.64M

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. The company's

The company's gross margin rose by 22% QoQ and by 21% YoY

ORTX's EPS is up by 25% year-on-year but it is down by 8% since the previous quarter

The equity has increased by 17% year-on-year but it has declined by 9% since the previous quarter

The revenue has plunged by 63% YoY and by 40% from the previous quarter

The gross profit has shrunk by 55% YoY and by 27% QoQ

What are the main financial stats of ORTX

Market
Valuations
Earnings

Shares outstanding

125.5M

Market cap

$159.38M

Enterprise value

$141.64M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.66

Price to sales (P/S)

135.71

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

118.82

Revenue

$1.19M

EBIT

-$138.68M

EBITDA

-$136.58M

Free cash flow

-$105.39M

Per share
Balance sheet
Liquidity

EPS

-$1.23

Free cash flow per share

-$0.83

Book value per share

$1.92

Revenue per share

$0.01

TBVPS

$2.75

Total assets

$355.66M

Total liabilities

$114.36M

Debt

$60.84M

Equity

$241.3M

Working capital

$247.22M

Debt to equity

0.25

Current ratio

6.59

Quick ratio

5.86

Net debt/EBITDA

0.13

Margins
Efficiency
Dividend

EBITDA margin

-11,458.1%

Gross margin

81.1%

Net margin

-11,900.7%

Operating margin

-11,987.5%

Return on assets

-40.8%

Return on equity

-57.9%

Return on invested capital

-50.1%

Return on capital employed

-44.5%

Return on sales

-11,634.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Orchard Therapeutics stock price performed over time

Intraday

-5.93%

1 week

-13.01%

1 month

-35.86%

1 year

-73.81%

YTD

-70.6%

QTD

-44.78%

How have Orchard Therapeutics's revenue and profit performed over time

Revenue

$1.19M

Gross profit

$967,000

Operating income

-$142.89M

Net income

-$141.86M

Gross margin

81.1%

Net margin

-11,900.7%

The net margin has dropped by 132% year-on-year and by 89% since the previous quarter

Orchard Therapeutics's operating margin has shrunk by 129% YoY and by 76% QoQ

The revenue has plunged by 63% YoY and by 40% from the previous quarter

The gross profit has shrunk by 55% YoY and by 27% QoQ

What is Orchard Therapeutics's growth rate over time

What is Orchard Therapeutics stock price valuation

P/E

N/A

P/B

0.66

P/S

135.71

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

118.82

ORTX's EPS is up by 25% year-on-year but it is down by 8% since the previous quarter

The price to book (P/B) is 70% less than the last 4 quarters average of 2.2

The equity has increased by 17% year-on-year but it has declined by 9% since the previous quarter

The revenue has plunged by 63% YoY and by 40% from the previous quarter

The P/S is 46% less than the last 4 quarters average of 252.3

How efficient is Orchard Therapeutics business performance

ORTX's return on sales has dropped by 129% year-on-year and by 90% since the previous quarter

The return on assets is up by 15% year-on-year but it has declined by 8% since the previous quarter

The ROIC has contracted by 12% from the previous quarter but it has grown by 4% YoY

Orchard Therapeutics's ROE has increased by 12% YoY but it has decreased by 9% from the previous quarter

What is ORTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ORTX.

How did Orchard Therapeutics financials performed over time

Orchard Therapeutics's total liabilities has increased by 25% YoY and by 14% QoQ

The total assets has grown by 19% YoY but it has contracted by 2.5% from the previous quarter

The debt is 75% smaller than the equity

The equity has increased by 17% year-on-year but it has declined by 9% since the previous quarter

ORTX's debt to equity is down by 11% YoY but it is up by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.